Squamous cell carcinoma of head and neck
Not recruitingStudy of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer
Study of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer
- Disease:Squamous cell carcinoma of head and neck
- Substances:PembrolizumabHUMAN IGG1 HEXAVALENT ANTIBODY AGAINST TNFRSF4
Italy- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Inhibrx Biosciences Inc.










